Experimental T-Cell therapy targets CMV in transplant patients
NCT ID NCT02982902
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental therapy that uses special immune cells (T-cells) from a donor to fight cytomegalovirus (CMV) infection in people who have had a stem cell transplant. The therapy aims to boost the patient's immune system to clear the infection. About 20 participants will be enrolled to check if the treatment is safe and possible to give.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
RECRUITINGCleveland, Ohio, 44106-5065, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells predict herpesvirus danger in transplant patients?
- Can specially grown immune cells from donors beat viruses that won't go away?
- Can Real-World data unlock clues to a deadly Post-Transplant complication?
- Immune cell levels may predict who will develop severe CMV after transplant
- Lab-Grown immune cells take aim at Life-Threatening viruses in vulnerable patients
- Hidden immune fire: could CMV or autoimmunity be fueling HIV-Related inflammation?